published meta-analysis   sensitivity analysis   studies

IFN beta-1a in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable deathsdetailed resultsDarazam, 2021 (REV) 0.83 [0.44; 1.54] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40] 1.14[0.96; 1.36]Darazam, 2021 (REV), Kalil (ACTT-3), 2021, SOLIDARITY (interferon), 202030%5,237moderatenot evaluable deaths (time to event analysis only)detailed resultsKalil (ACTT-3), 2021 1.74 [0.51; 5.93] 1.74[0.51; 5.93]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvementdetailed resultsDarazam, 2021 (REV) 0.73 [0.47; 1.13] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 0.92[0.71; 1.19]Darazam, 2021 (REV), Kalil (ACTT-3), 2021241%1,137moderatenot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.01[0.79; 1.29]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam, 2021 (REV) 0.73 [0.47; 1.13] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 0.92[0.71; 1.19]Darazam, 2021 (REV), Kalil (ACTT-3), 2021241%1,137moderatenot evaluable death or ventilationdetailed resultsSOLIDARITY (interferon), 2020 1.05 [0.90; 1.23] 1.05[0.90; 1.23]SOLIDARITY (interferon), 202010%4,100NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-06 18:22 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 881,904 - roots T: 290